EUVIMEDEUVIMED entdecken
Open Access

GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy

Hanxue Huang, Junyan Liu, Qi Xiao, Chenxue Mao, Lei She, Lulu Yu, Bing Yu, Mengrong Lei, Ying Gao, Baimei He, Pinhua Pan, Xi Li und 2 weitere

Acta Biochimica et Biophysica Sinica · 2025

DOI: 10.3724/abbs.2025013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2025. Verfasst von Hanxue Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya…. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum-based chemotherapy remains the mainstay for non-small cell lung cancer (NSCLC), but it frequently causes dose-limiting myelosuppression, with significant individual variability in susceptibility. However, the genetic basis of myelosuppression side effects remains elusive, greatly hindering personalized therapeutic approaches. In this study, we perform a comprehensive genome-wide association analysis on 491 NSCLC patients receiving platinum-based chemotherapy, examining 4,690,998 single-nucleotide polymorphisms (SNPs) to identify relevant genetic variants. LDBlockShow, FUMA, and MAGMA are utilized to explore linkage disequilibrium, expression quantitative trait loci (eQTLs), chromatin interaction, and conduct gene-based and gene set-based analysis of candidate SNPs. The GWAS results reveal that rs6856089 and its linked SNPs are significantly associated with platinum-based chemotherapy-induced myelosuppression. Specifically, patients with the A allele of rs6856089 have a significantly lower risk of myelosuppression (odds ratio (OR) = 0.1300, P = 7.59 × 10–8). Furthermore, gene-based analysis reveals that EMCN (P = 2.47 × 10–5), which encodes endomucin, a marker for hematopoietic stem cells, might mediate myelosuppression. This study provides a scientific basis for the individual differences in platinum-based chemotherapy-induced myelosuppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genome-Wide Association StudyCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPlatinumHumansPolymorphism, Single NucleotideFemaleMaleMiddle AgedAgedQuantitative Trait LociLinkage Disequilibrium

Stichwörter der Autor:innen

genome-wide association analysismyelosuppressionnon-small cell lung cancerplatinum-based chemotherapy

Substanzen

Platinum

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Institute of Clinical Pharmacology, Engineering Research Center for Applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha 410078, China.
  • Departments of Orthopaedics, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Departments of Gerontology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Departments of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.

Zitieren

APA

Huang, H., Liu, J., Xiao, Q., Mao, C., She, L., Yu, L., Yu, B., Lei, M., Gao, Y., He, B., Pan, P., Li, X., Yin, J., & Liu, Z. (2025). GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2025013

Vancouver

Huang H, Liu J, Xiao Q, Mao C, She L, Yu L, et al. GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy. Acta Biochimica et Biophysica Sinica. 2025. doi:10.3724/abbs.2025013

BibTeX
@article{Huang2025,
  author = {Huang, Hanxue and Liu, Junyan and Xiao, Qi and Mao, Chenxue and She, Lei and Yu, Lulu and Yu, Bing and Lei, Mengrong and Gao, Ying and He, Baimei and Pan, Pinhua and Li, Xi and Yin, Jiye and Liu, Zhaoqian},
  title = {GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy},
  journal = {Acta Biochimica et Biophysica Sinica},
  year = {2025},
  doi = {10.3724/abbs.2025013}
}
Kostenlos starten →